Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
14 mars 2017 19h46 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Mar 14, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the second cohort comprising six patients has now been...
USA Patent Grants for IMP321 in Cancer
28 févr. 2017 19h30 HE
|
PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Feb 28, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 9,579,382 entitled "Use of Recombinant...
First Half 2017 Operational Update
24 févr. 2017 02h13 HE
|
PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Feb 24, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Highlights
Positive recruitment rates for TACTI-mel and AIPAC...
Prima BioMed Receives ~A$860,000 Tax Credit Payment From French Government
12 févr. 2017 20h50 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Feb 12, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), is pleased to announce that its French subsidiary, Immutep S.A.S., has...
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
22 janv. 2017 19h00 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 22, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the submission titled "TACTI-mel, Two ACTive Immunotherapies...
Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
19 janv. 2017 18h07 HE
|
PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Jan 19, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced the first patient has been dosed as part of the enlarged...
Prima BioMed to Maintain NASDAQ Listing
18 janv. 2017 02h02 HE
|
PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Jan 18, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock...
Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
11 janv. 2017 18h41 HE
|
PRIMA BIOMED LTD
SYDNEY, AUSTRALIA--(Marketwired - Jan 11, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced that the first patient has been dosed for the second cohort...
Prima BioMed Enters New Material Transfer Agreement With CYTLIMIC
05 janv. 2017 02h48 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 5, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, today announced that it has entered into a new collaboration agreement...
Prima Announces New Product Candidate IMP761 -- A LAG-3 Agonist Antibody
02 janv. 2017 18h37 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 2, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces that it has developed a new early stage product candidate, a...